10 Participants Needed

Pelashield PainGuard for Hidradenitis Suppurativa

NR
Overseen ByNeil Reddy, BS
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Rutgers, The State University of New Jersey
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if a new wound dressing, Pelashield™ PainGuard™, can improve healing after surgery for people with Hidradenitis Suppurativa (HS) compared to the current standard dressing. HS is a painful skin condition that sometimes requires surgery. The new dressing contains silver to combat bacteria and lidocaine to reduce pain. The trial seeks adults with HS who need surgery and can attend follow-up visits. As an unphased trial, this study allows patients to contribute to innovative research that could enhance post-surgical healing for HS.

What prior data suggests that Pelashield™ PainGuard™ is safe for wound healing after surgery?

Research shows that Pelashield™ PainGuard™ prioritizes safety. It contains silver to reduce bacteria and lidocaine to manage pain. Pelashield™ has been used to treat burn wounds, demonstrating its safety and effectiveness for complex wound care. Although specific data from past studies on its use in hidradenitis suppurativa (HS) surgery is lacking, its ingredients have been well-researched for safety.

This trial is not in a traditional clinical phase, indicating that Pelashield™ PainGuard™ is already deemed safe enough to test for effectiveness in this context. Current knowledge suggests no major safety concerns. However, it is important to consult a healthcare provider to understand how it might affect personal health.12345

Why are researchers excited about this trial?

Unlike the standard treatments for Hidradenitis Suppurativa, which often include antibiotics, anti-inflammatory medications, and sometimes biologics, Pelashield™ PainGuard™ is unique because it integrates directly with surgical procedures. This treatment involves applying Pelashield™ PainGuard™ to the surgical wound after wide excision of affected tissue, potentially offering enhanced postoperative protection and pain management. Researchers are excited about this approach because it may provide a more efficient healing process and better pain control compared to traditional methods.

What evidence suggests that Pelashield™ PainGuard™ is effective for healing after surgery for Hidradenitis Suppurativa?

Research has shown that Pelashield™ PainGuard™ might aid healing after surgery for hidradenitis suppurativa (HS), a painful skin condition. The dressing contains silver to fight bacteria and lidocaine to reduce pain. This combination aims to accelerate the growth of new, healthy tissue. Early results suggest that PainGuard™ could reduce the need for strong pain medications after surgery. This trial tests whether Pelashield™ PainGuard™ can offer better outcomes for HS patients compared to the current standard treatment.678910

Who Is on the Research Team?

MG

Mark Granick, MD

Principal Investigator

New Jersey Medical School

Are You a Good Fit for This Trial?

This trial is for individuals with Hidradenitis Suppurativa (HS) who require surgery. It's designed to compare two wound dressings post-surgery: Restrata®, the standard treatment, and Pelashield™ PainGuard™, which has silver and lidocaine.

Inclusion Criteria

Ability to provide informed consent in English
I am an adult with HS needing major surgery.
I am willing and able to go to follow-up visits after my surgery.

Exclusion Criteria

Pregnancy or active breastfeeding
I do not have an active infection or sepsis at the time of surgery.
Known allergy or hypersensitivity to wound matrix components (polyvinyl alcohol), local anesthetics, or silver
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Stage 1 Surgery and Wound Matrix Application

Perform wide excision of HS-affected tissue and apply wound matrix (Pelashield™ PainGuard™ or Restrata®) to cover the surgical wound

1 day
1 visit (in-person)

Postoperative Period 1

Monitor for surgical site infection and opioid analgesic usage from Stage 1 excision through day before Stage 2 closure

up to 8 weeks

Stage 2 Surgery and ReCell Application

Debridement and definitive closure with ReCell application

1 day
1 visit (in-person)

Postoperative Period 2

Monitor opioid analgesic usage and ReCell skin graft incorporation

30 days post-Stage 2

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Pelashield™ PainGuard™

Trial Overview

The study aims to determine if Pelashield™ PainGuard™ leads to better healing outcomes than Restrata® by assessing new tissue formation speed, readiness for skin grafting surgery, infection rates, and opioid pain medication needs after HS surgery.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Pelashield™ PainGuard™ GroupExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Rutgers, The State University of New Jersey

Lead Sponsor

Trials
471
Recruited
81,700+

Citations

Trends in Hidradenitis Suppurativa Disease Severity and ...

Results: The HS Clinical Response (HiSCR) score (18/41, 44%) was the most commonly used instrument for disease severity, followed by the ...

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

Specific Aim: To evaluate whether Pelashield™ PainGuard™, when used in place of Restrata® for wide excision of hidradenitis suppurativa, results ...

3.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/40601333/

A Living Systematic Review and Network Meta-Analysis

Main outcomes and measures: Primary efficacy, safety, and tolerability outcomes were Hidradenitis Suppurativa Clinical Response (HiSCR)-50 ...

Outcomes Vary by Surgical Intervention Used for ...

Investigators assessed the therapeutic efficacy of various surgical interventions in patients with HS on patient-centered outcomes, ...

The Key to Better Outcomes in Hidradenitis Suppurativa

Topical resorcinol, a keratolytic agent, has shown promise in reducing pain and the duration of flares in some patients. As the disease progresses or in cases ...

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

Pelashield™ PainGuard™, a newer dressing that contains silver to reduce bacteria and lidocaine to help with pain. The goal of this research is ...

HidraWear Study for Hidradenitis Suppurativa Wounds

This pilot study will evaluate usability - the safety, efficacy and performance of HidraWear AX in the home setting. Quality of life, ease of use and comfort of ...

Pelashield™ - Burn Wounds

Pelashield™ is a fully synthetic, hydrophilic, antimicrobial matrix specifically designed for complex challenges in burn wounds.1 Learn how Pelashield™ can ...

SAR445399 in Hidradenitis Suppurativa - Clinical Trials Registry

The purpose of this study is to assess the efficacy and safety of two doses of SAR445399 compared with placebo in adult participants with moderate to severe ...

A Review of Hidradenitis Suppurativa in Special Populations

Biologic safety data for treating of HS during pregnancy are limited, but many biologics have been tested in pregnant patients for other inflammatory conditions ...